PARIS |
PARIS (Reuters) – Sanofi pronounced on Monday regulators had authorized Lyxumia, an injectable diabetes treatment, for sale in Europe.
Also famous by a general name lixisenatide, a drug is taken once a day in and with other drugs or insulin by patients who are differently not means to control their blood sugarine levels.
The drug is one of a new products a French drug builder is betting on to revive expansion after losing several blockbusters to general competition.
Lyxumia showed profitable impact on blood sugarine levels and control, as good as weight loss, according to 11 clinical trials carried out in some-more than 5,000 form 2 diabetes patients.
The selling permission for Lyxumia is germane to a 27 member states of a European Union, as good as Iceland, Lichtenstein and Norway, and applications are also tentative in several other countries.
Sanofi also pronounced final week that it expects a U.S. Food and Drug Administration to order on a focus for a new mixed sclerosis diagnosis called Lemtrada by a second half of this year.
(Reporting by Leila Abboud; Editing by Mike Nesbit)
